The National Inflammatory Bowel Disease (IBD) Clinical Care Pathways (CCP) equip health care professionals with evidence-based guidelines to standardize and enhance IBD care across Canada.
Developed in collaboration with Dr. Karen Kroeker (University of Alberta), Dr. Remo Panaccione (University of Calgary), Dr. Cynthia Seow (University of Calgary), and the IBD CCP working group, these 17 structured pathways support optimal patient care. They address key areas, including the use of corticosteroids, health maintenance, vaccinations, preconception and pregnancy considerations in IBD and colon cancer surveillance. Additionally, they provide guidance on initiating and maintaining advanced therapies to ensure continuity of care for patients requiring long-term treatment.
Additionally, interactive versions are now available for select pathways, including the induction and maintenance of advanced therapies, the use of immunomodulators and corticosteroids, and the management of loss of response to treatment. More dynamic versions are forthcoming to support usability in clinical practice.
By adopting these evidence-informed pathways, healthcare providers can facilitate early intervention, reduce complications, and improve patient outcomes. The CCPs align with the latest clinical evidence, promoting consistent, high-quality, and patient-centered management of IBD.
To explore all 17 pathways available in English and French, visit National IBD Clinical Care Pathways.
For any questions or further information, please contact us at research@crohnsandcolitis.ca